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CITED2 affects leukemic cell survival by interfering with
p53 activation
Katharina Mattes1,2, Gerbrig Berger1,2, Marjan Geugien1, Edo Vellenga1 and Hein Schepers*,1
CITED2 (CBP/p300-interacting-transactivator-with-an-ED-rich-tail 2) is a regulator of the acetyltransferase CBP/p300 and elevated
CITED2 levels are shown in a number of acute myeloid leukemia (AML). To study the in vivo role of CITED2 in AML maintenance,
AML cells were transduced with a lentiviral construct for RNAi-mediated knockdown of CITED2. Mice transplanted with CITED2-
knockdown AML cells (n= 4) had a significantly longer survival compared to mice transplanted with control AML cells (Po0.02).
In vitro, the reduction of CITED2 resulted in increased p53-mediated apoptosis and CDKN1A expression, whereas BCL2 levels were
reduced. The activation of p53 upon CITED2 knockdown is not a direct consequence of increased CBP/p300-activity towards p53,
since no increased formation of CBP/p300/p53 complexes was demonstrated and inhibition of CBP/p300-activity could not rescue
the phenotype of CITED2-deficient cells. Instead, loss of CITED2 had an inhibitory effect on the AKT-signaling pathway, which was
indicated by decreased levels of phosphorylated AKT and altered expression of the AKT-pathway regulators PHLDA3 and SOX4.
Notably, simultaneous upregulation of BCL2 or downregulation of the p53-target gene PHLDA3 rescued the apoptotic phenotype in
CITED2-knockdown cells. Furthermore, knockdown of CITED2 led to a decreased interaction of p53 with its inhibitor MDM2, which
results in increased amounts of total p53 protein. In summary, our data indicate that CITED2 functions in pathways regulating p53
activity and therefore represents an interesting target for AML therapy, since de novo AML cases are characterized by an
inactivation of the p53 pathway or deregulation of apoptosis-related genes.
Cell Death and Disease (2017) 8, e3132; doi:10.1038/cddis.2017.548; published online 26 October 2017
Acute myeloid leukemia (AML) is a genetically heterogeneous
disease that is characterized by an accumulation of immature
myeloblasts in the bone marrow. Despite the variety in the
mutational background, the transcriptional regulator CITED2
(CBP/p300-interacting-transactivator-with-an-ED-rich-tail 2) is
found to be upregulated in the majority of AML cases.1 As
demonstrated by conditional knockout studies, CITED2 is
essential for the maintenance of adult hematopoietic stem
cells during normal haematopoiesis, whereas it is dispensable
in more committed cells.2 Notably, recent data strengthened
the hypothesis that CITED2 has also critical functions in
maintaining human leukemic cells, since knockdown of
CITED2 in AML cells inhibited AML engraftment in vivo, when
competed with control cells.1 These findings suggest that
CITED2 might have an important role in the survival of the
leukemic stem cell (LSCs) – those AML cells that fail to be
targeted sufficiently and most likely cause disease relapse.
CITED2 was originally identified and characterized as a
protein binding to CH1 domain of the acetyltransferase CBP/
p300.3,4 Acetylation of histones and non-histone proteins is
crucial for eukaryotic cells to regulate transcription. By binding to
CBP/p300, CITED2 was shown to regulate the CBP/p300-
mediated transactivation of multiple transcription factors such as
HIF1α,3 NF-κB,5 LHX2,6 TFAP2,7MYC,8 PPARα9 andSMAD2.10
Presence of CITED2 can enhance or repress the target gene
expression of these transcription factors. In case of HIF1α and
NF-κB, CITED2 has been described to compete for p300 and
thereby block HIF1α- and NF-κB-mediated transcription.3,5 For
most other transcription factors, CITED2 acts as a co-activator of
transcription by recruiting CBP/p300 to the transcription factor
target sites.Whereas increased expression of CITED2 has been
described to facilitate MYC- and PPARα-mediated cell-cycle
progression,8 low expression of CITED2 is associated with an
increase of cell death, for example by impaired SMAD2- and
TFAP2 signaling.10 Interestingly, loss of CITED2 expression has
been reported to lead to increased activation of the tumor
suppressor protein p53,12 which is acetylated and co-activated
by CBP/p300.Wu et al.12 suggested increased formation of p53-
CBP/p300 complexes in the absence of CITED2. However, other
studies reported decreased p300 function in CITED2-deficient
cells,13 and therefore the role of CITED2 in p53 signaling is still
unclear.
Here we report that loss of CITED2 severely impairs AML
cell survival by induction of p53-mediated apoptosis. Interest-
ingly, loss of CITED2 activates the p53 pathway independent
of CBP/p300-mediated acetylation of p53. Instead, reduction
of CITED2 levels impairs cell survival by interfering with the
AKT signal transduction pathway.
Results
Knockdown of CITED2 in CD34+ AML cells impairs
leukemia development. In order to demonstrate that
CITED2 truly impacts the survival and maintenance of
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leukemia initiating cells (LICs, or LSCs), AML cells were
transduced with a lentiviral GFP-vector expressing a short
hairpin targeting CITED2 (shCITED2) or a control vector. The
hairpin was selected based on previous data demonstrating
that various shCITED2-constructs resulted in similar
phenotypes.1 After transduction, GFP-positive cells were
sorted and subsequently transplanted into NSG mice (n=4)
(Figure 1a). Mice which only received sorted shCITED2-
transduced leukemic cells have a significantly longer survival
as compared to mice that only received control-transduced
leukemic cells (138 versus 256 days Po0.02, Figure 1b).
Eventually, engraftment of human AML cells and leukemia
development was observed in both control- and shCITED2
mice (Supplementary Figure S1); however, the progression in
shCITED2 mice was delayed (Figure 1c). It appeared that the
GFP-positive shCITED2-AML cells that eventually did engraft
did not show a reduction of CITED2 levels and therefore
most likely have escaped sufficient knockdown of CITED2
(Figure 1d), indicating that CITED2 knockdown impacts the
survival and maintenance of leukemia initiating cells.
Loss of CITED2 triggers apoptosis in leukemic cells.
Similar suppressive effects of CITED2 reduction were
observed in the leukemic cell lines NB4 and MOLM-13
(Figure 2a, Supplementary Figure S2A). To gain a first insight
into the cause of reduced cell expansion, the effects of
CITED2 knockdown on apoptosis and cell-cycle distribution
were analyzed in NB4 or MOLM-13 cells. A strong increase of
Annexin V+ cells was observed in shCITED2 cells compared
to control cells (Figure 2b, Supplementary Figure S2B),
whereas no significant changes in cell-cycle distribution could
be demonstrated (Figure 2c, Supplementary Figure S2C).
Figure 1 Knockdown of CITED2 in AML cells impairs leukemia development. (a) Schematic overview of lentiviral shRNA transductions for mice transplantation experiments.
(b) Kaplan–Meier curve indicating the survival of mice transplanted with sorted control- or shCITED2- transduced CD3-depleted AML cells. n= 4, Po0.02. (c) NSG mice were
analyzed for the presence of human engraftment at indicated time points after transplantation with control- or shCITED2-transduced AML cells. Percentage of human CD45+ cells
in peripheral blood is shown. Survival of the individual mice is indicated in brackets. (d) FACS plots indicating sorting strategy for human GFP+ cells from sacrificed NSG mice (left
panel) and Q-PCR analysis for CITED2 in sorted cells (right panel) are shown. Error bars indicate s.d. of Q-PCR triplicates
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shCITED2-mediated cell death is triggered by a p53-
dependent pathway. Previously, microarray analysis of
shCITED2-transduced versus control-transduced CD34+
cord blood cells was performed to identify the molecular
pathways that are particularly dependent on CITED2 levels
(GSE47218).1 Further analysis of this data set revealed a
significant enrichment of p53 target genes among the
upregulated genes after CITED2 knockdown (Figure 3a).
Gene expression analyses by Q-PCR in shCITED2-
transduced NB4 and MOLM-13 cells confirmed an upregula-
tion of several p53 targets such as CDKN1A, BTG2, ABHD4
and PHLDA3, whereas the p53-regulated anti-apoptotic
protein BCL2 was strongly down regulated (Figure 3b,
Supplementary Figure S3A). Simultaneous knockdown of
p53 and CITED2 rescued the increased apoptosis levels in
NB4 and MOLM-13 cells (Figures 3c and d, Supplementary
Figure S3B), while lentiviral overexpression of p53 poten-
tiated shCITED2-mediated apoptosis (Figure 3e). Impor-
tantly, decreasing CITED2 levels had no impact on
apoptosis levels of leukemic cell lines that are devoid of
p53, such as K562 (Figure 3d, right panel).
Activation of p53 signaling in CITED2 knockdown cells is
not due to direct CBP/p300-mediated p53 acetylation. As
activated p53 signaling turned out to be a crucial factor in the
shCITED2-mediated cell death and CITED2 has been
described to co-regulate binding of CBP/p300 to its targets,
we questioned whether CBP/p300-mediated acetylation on
C-terminal lysine 382 of p5314 is involved. In shCITED2-
transduced NB4 cells, increased acetylation of p53 on the
C-terminal lysine 382 was observed compared to control cells
(Figure 4a). Next, it was investigated whether CITED2 directly
interferes with p53 acetylation by either (i) recruiting
deacetylases (HDACs, SIRTs) to the p300/p53 complex, or
(ii) by blocking the binding of CBP/p300 to p53. By performing
co-immunoprecipitation (IP) assays with lysates from trans-
duced NB4 cells, binding of CBP/p300 to CITED2 as well as
binding of CBP/p300 to p53 was observed (Supplementary
Figure 2 Loss of CITED2 triggers apoptosis in leukemic cells. (a) The leukemic cell lines MOLM-13 and NB4 were transduced with a GFP-expressing control- or shCITED2
construct. The number of GFP+ cells over time is shown. Error bars indicate s.d. of three individual experiments; *Po0.05. (b) Annexin V staining of NB4 and MOLM-13 cells
4–5 days after transduction with shCITED2. FACS plots of an individual experiment (left panels) and average percentage of Annexin V-positive cells from multiple experiments
(right panels) is shown. Error bars indicate s.d. (n= 6 MOLM-13, n= 4 NB4). ***Po0.001, *Po0.05. (c) Cell-cycle analysis of control- and shCITED2-transduced MOLM-13 (left
panel) and NB4 cells (right panel)
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Figure S4A), but no evidence was obtained for a CBP/p300/
CITED2/p53 interaction (Figure 4b). In addition, no interac-
tion of CITED2 with HDAC1, HDAC2, or the acetyltransferase
P/CAF could be demonstrated (Figure 4b, Supplementary
Figure S4B). The knockdown of CITED2 did not lead to an
increased binding of p53 to CBP or p300 (Supplementary
Figure S4C). Finally it was shown that treatment of leukemic
cells with the CBP/p300 inhibitor C646 for 24 h did not rescue
Figure 3 shCITED2-mediated cell death is triggered by a p53-dependent pathway. (a) Gene set enrichment analysis (GSEA) of genome-wide gene expression from CD34+
cord blood cells transduced with a control- or shCITED2 vector revealed an enrichment of p53 target genes. (b) Q-PCR of p53 targets in NB4 and MOLM-13 cells 4–5 days after
transduction with the shCITED2 vector. Error bars indicate s.d. of triplicates from representative Q-PCR. (c) MOLM-13 cells were double-transduced with GFP and mCherry
expressing shRNA vectors to knockdown CITED2 and/or p53 and stained for Annexin V 4–5 days after transduction. Representative FACS plots indicating the percentage of
Annexin V-positive cells are shown. (d) Percentage of Annexin V-positive cells in shCITED2/shp53-transduced MOLM-13 (n= 5) and K562 (n= 3) cells 5 days after transduction
is shown. Error bars indicate s.d. *Po0.05, ***Po0.001; n.s.= not significant. (e) MOLM-13 cells were co-transduced with a construct for CITED2 knockdown and p53
overexpression. Percentage of Annexin V-positive cells 3 days after transduction is indicated
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the shCITED2-mediated effects on p53 acetylation, or
PHLDA3- and BCL2 expression (Figure 4c). These results
suggest that the effects of shCITED2 are independent of
direct CBP/p300-mediated p53 activation. This was con-
firmed by simultaneous transduction of shCITED2 cells with
short hairpins against p300, CBP or both, which did not affect
levels of p53 acetylation (Figure 4d). Furthermore, knock-
down of CITED2 in CBP/p300-deficient cells still led to an
approximately twofold increase in apoptosis (Figure 4e).
These data propose that p53 activation in shCITED2 cells is
not a direct consequence of interfering with its acetylation
state. This hypothesis was further supported by the fact that
Figure 4 Increased p53 activation in CITED2-knockdown cells is not directly mediated by CBP/p300. (a) Western blot analysis for ac-p53 (Lys382) of sorted GFP+ NB4 cells
transduced with a control- or shCITED2-expressing construct. Cells were sorted 4 days after transduction. Numbers indicate quantification of the ac-p53 signal normalized to
Actin. (b) GFP-coimmunoprecipitation (IP) experiment of CITED2:EGFP-expressing NB4 cells and western blot analysis for indicated antibodies. Red rectangle highlights the
lane showing interactions between CITED2 and the indicated proteins. (c) NB4 cells were transduced and sorted as in (a). Cells were treated with indicated concentration of the
CBP/p300 inhibitor C646 for 24 h before sorting. Western blot analysis for ac-p53 (left panel) and Q-PCR analysis for PHLDA3 (middle panel) and BCL2 (right panel) expression is
shown. Error bars indicate s.d. of Q-PCR triplicates. (d) NB4 cells were simultaneously transduced with indicated combinations of shRNA constructs for downregulation of
CITED2, EP300 and CBP. Western blot analysis for indicated antibodies of sorted cells is shown. (e) Annexin V staining of MOLM-13 cells transduced as in (d). Percentage of
Annexin V-positive cells is indicated. Error bars indicate s.d. of two individual experiments; *Po0.05
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interference with other acetyltransferases that target p53
(P/CAF,15 GCN5,16 TRRAP,17 TIP6018,19 or MOZ20) did not
rescue the phenotype of CITED2-low cells. There was no
increase in GCN5 binding to ac-p53 in NB4 cells with CITED2
knockdown (Supplementary Figure S4D) and treatment of
shCITED2-transduced MOLM-13 cells with the TIP60/MOZ
inhibitor MG-149 could not rescue the apoptotic phenotype of
cells upon CITED2 knockdown (Supplementary Figure S4E).
Targeting CITED2 in AML
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CITED2 knockdown mediates a p53/PHLDA3/BCL2-
dependent decrease in AKT signaling. As depicted in
Figure 5a, knockdown of CITED2 also leads to an increased
amount of total p53 protein. The ubiquitin ligase MDM2
has a central role in regulating p53 stability by binding to p53
and thereby either directly inhibiting its transcriptional
activity or promoting proteasome-mediated degradation of
p53 (reviewed in Kruse and Gu21 and Manfredi22). By
performing IP in MOLM13 cells, it was demonstrated that
knockdown of CITED2 results in decreased interaction
between MDM2 and p53 (Figure 5a). In line with these data,
shCITED2-transduced cells had an increased sensitivity to
treatment with Nutlin3a, an inhibitor of the MDM2–p53
interaction (Figure 5b). The pro-survival AKT signaling
pathway23,24 is promoting p53-inhibiting functions of MDM2
(Figure 5c). Interestingly, knockdown of CITED2 resulted in
strong increase in mRNA expression of PHLDA3 (Figure 3b),
a known repressor of AKT signaling.25 PHLDA3 interferes
with binding of AKT to second messenger molecules at the
cell membrane and thus prevents AKT phosphorylation and
activation (Figure 5c). In line with these data, decreased AKT
phosphorylation, and thus decreased AKT activation was
observed in CITED2-knockdown cells by western blotting
(Figure 5d). Besides upregulation of PHLDA3, upregulation of
the AKT-inhibitor TXNIP26 and downregulation of the AKT-
activator SOX427 was observed (Figure 5e). Interestingly,
simultaneous knockdown of p53 rescued the shCITED2-
mediated increase in PHLDA3 expression, whereas
shCITED2-mediated alteration of BCL2, SOX4 and TXNIP
was found to be p53-independent (Figure 5e). To further
investigate the involvement of the AKT-signaling pathway in
the shCITED2-mediated phenotype, transduced shCITED2
cells were simultaneously transduced with a short hairpin
against PHLDA3 or a lentiviral construct overexpressing BCL2
(Supplementary Figure S5). Simultaneous knockdown of
CITED2 and PHLDA3 partially rescued the shCITED2-
mediated induction of cell apoptosis (Figure 5f upper panel),
indicating that the increased expression of PHLDA3 contrib-
uted to the CITED2-mediated effects on cell survival. Strikingly,
simultaneous upregulation of BCL2 in CITED2 knockdown cell
could almost completely rescue the apoptotic phenotype
(Figure 5f lower panel). These data demonstrate that both
upregulation of PHLDA3 and downregulation of BCL2 are
critical events in shCITED2-mediated apoptosis in AML cells.
Discussion
The results of our study demonstrate that reduction of CITED2
levels impairs the survival of leukemic cells, in part due to
induction of p53-mediated apoptosis. Notably, AML cells are
characterized by elevated CITED2-expression and the pre-
sent study highlights the importance of CITED2 levels in
regulating cell survival pathways. It appeared that the
activation of the p53 pathway is not due to increased CBP/
p300-mediated p53 acetylation, which can stabilize p53
protein expression. Although an overall increase of acetylated
p53 in CITED2-deficient cells was detected, treatment of cells
with the CBP/p300 inhibitor C646 as well as RNAi-mediated
knockdown of CBP/P300 could not rescue the effect on p53-
mediated apoptosis and target gene expression, indicating
that p53 activation upon CITED2 knockdown is not due to
increased activity of CBP/p300 towards p53. This is in contrast
to a previous study12 suggesting an increased formation of
CBP/p300/p53 complexes in CITED2-deficient cells. Also
increased deacetylation by SIRT1 or HDAC1 and HDAC2 in
CITED2-knockdown cells could not be demonstrated, sug-
gesting that the detected increase in acetylated p53 ismainly a
result of an increased amount of total p53 protein.
Importantly, reactivation of p53 function represents a
relevant strategy for AML therapy, since approximately 90%
of de novo AML cases do not show a mutation in the p53
gene,28 but are rather characterized by an inactivation of the
p53 pathway or deregulation of apoptosis-related genes.29We
demonstrated that reduction of CITED2 levels results in a
decreased interaction between p53 and its inhibitor MDM2.
Disruption of the MDM2–p53 interaction has been reported to
serve as a promising tool in AML therapy30,31 and various
small molecules targeting p53 are currently implemented in
the treatment of hematological malignancies to improve the
efficiency of conventional cytotoxic drugs.32 One of the
molecules used for targeting p53 is the MDM2–p53 inhibitor
Nutlin3a and in this study we demonstrated that reduction of
CITED2 expression sensitizes AML cells to Nutlin3a
treatment.
Inactivation of p53 signaling can be caused by aberrant
activation of the AKT signaling pathway,33 which controls
proliferation and differentiation of hematopoietic cells. Notably,
constitutive activation of AKT (indicated by increased phos-
phorylation of AKTon Ser473 and Thr308) is found in 50–70%
of AML patients.34 Multiple studies in the course of the last
years demonstrated that aberrant activation of AKT signaling
plays a critical role for the survival and maintenance of AML
cells (reviewed in Fransecky et al.,35 Park et al.36 and
Birkenkamp et al.37). Whereas mutations of components
involved in AKT downstream signaling are rarely found in AML,
mutations of membrane-bound proteins upstream of AKT that
trigger its activation are common.28 A frequent source of AKT
deregulation in AML are mutations in receptor tyrosine
Figure 5 CITED2 knockdown mediates decrease in AKT-signaling in a p53/PHLDA3/BCL2-dependent manner (a) p53 co-IP of sorted control- or shCITED2-transduced
MOLM-13 cells with subsequent western blot analysis for MDM2 (left panel). Right panel indicates quantified MDM2–p53 interaction. Error bars indicate s.d. from two individual
experiments. (b) Percentage of Annexin V-positive cells of control- or shCITED2-transduced MOLM-13 cells after incubation with indicated concentration of the inhibitor Nutlin3a
for 4 h. n= 2; error bars indicate s.d.; *Po0.05. (c) Schematic excerpt of the AKT signaling pathway: AKTactivation requires binding of AKT to second messenger molecules
(PIP3) at the cell membrane which eventually leads to expression of the pro-survival gene BCL2 and increased formation of MDM2–p53 complexes leading to p53 degradation.
Binding of the p53 target PHLDA3 to PIP3 interferes with that process. (d) Western blot analysis of NB4 cells for p-AKT expression after lentiviral knockdown of CITED2. (e)
Q-PCR for indicated genes in shCITED2-, shp53 or shCITED2/shp53-transduced cells. Error bars indicate Q-PCR triplicates. (f) MOLM-13 cells transduced with a short hairpin
construct against CITED2 in combination with a short hairpin against PHLDA3 or a lentiviral construct for overexpression of BCL2 were stained for Annexin V. FACS plots of an
individual experiment (left panels) and average percentage of Annexin V-positive cells at several days after transduction (right panels) are shown. Error bars indicated s.d. (n= 2);
*Po0.05, ***Po0.001
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kinases such as presence of FLT3-ITD38 or aberrant IGF1/
IGF1-R signaling.39 Compounds that interfere with AKT
signaling are currently used for AML therapy; however, further
understanding of this pathway in order to improve drug
development is still needed.
Notably, our present study indicates that CITED2 is acting in
p53-dependent, as well as in p53-independent pathways.
Reduction of CITED2 levels was shown to interfere with AKT
signaling on multiple levels (summarized in Figure 6). Whereas
upregulation of the p53-target gene and AKT-inhibitor PHLDA3
appeared to be a direct consequence of increased p53 protein
levels, upregulation of the AKT-inhibitor TXNIP and down-
regulation of the AKT-activatorSOX4 uponCITED2 knockdown
occurred in a p53-independent manner. These findings are in
line with p53-ChIP-Seq data indicating that there is no p53-
binding at the TXNIP- and SOX4 promoter region.40 The
transcription factor SOX4 binds to the promoter region of
multiple components of the AKT signaling pathways and
facilitates their transcription,27 whereas TXNIP has been shown
to play a role in activating PTEN26 – an important antagonist of
AKT activation – which can directly interfere with MDM2.41,42
Interestingly, SOX4 and CITED2 expression are both induced
by TGF-β signaling, and the CITED2-interaction partner
SMAD2 was found to bind to the SOX4 promoter region,
indicating that SOX4 and CITED2 might indeed function in the
same signaling pathway.43 Further evidence for a potential
CITED2-SOX4axis came from the finding that decreased levels
of the CITED2 inhibitor PU.11 had a synergistic effect with
SOX4 overexpression in promoting murine myeloid leukemia.44
Moreover, we identified the p53-independent downregula-
tion ofBCL2 to be a crucial factor in the apoptotic phenotype of
CITED2-knockdown cells. BCL2 overexpression is a hall mark
of AML and does not only contribute to AML pathogenesis but
also plays an important role in therapy resistance (reviewed in
Tzifi et al.45). Previous in vitro studies demonstrated that AML
cells are very sensitive to BCL2 inhibition.46 Notably, AKT
signaling is closely interconnected with members of the BCL2
family47 and a combination of AKT- and BCL2-inhibitors in
AML treatment could represent a beneficial combination.48
Therefore, components that regulate these pathways repre-
sent potential therapeutic targets.
In summary, we identified that reduction of CITED2
expression interferes with signaling pathways commonly
deregulated in AML. Therefore, CITED2 represents a novel,
potential target for AML therapy and it will be of interest to
study the detailed mechanisms of CITED2-mediated inter-
ference with AKT/BCL2/p53 signaling.
Materials and Methods
Isolation of primary cells. Cord blood (CB) CD34+ cells were derived from
neonatal cord blood from healthy full-term pregnancies after informed consent from
the Obstetrics departments of the Martini Hospital and University Medical Center in
Groningen, The Netherlands. AML blasts from peripheral blood cells or bone
marrow cells from untreated patients with AML were studied after informed consent
and the protocol was approved by the Medical Ethical Committee. CB and AML
mononuclear cells were isolated by density gradient centrifugation and CD34+ cells
were selected using the MACS CD34 microbead kit on autoMACS (Miltenyi Biotec,
Amsterdam, the Netherlands).
Cell cultures. The NB4 and MOLM-13 leukemic cell-lines (DSMZ: ACC 207
and 554) were cultured in RPMI1640 (Lonza, Leusden, the Netherlands, containing
L-glutamine) supplemented with 10% FCS and 100 U/ml penicillin/streptomycin.
CD34+ selected CB cells were cultured in HPGM (Lonza) supplemented with SCF,
FLT-3 ligand and N-Plate (Amgen, Breda, the Netherlands) (100 ng/ml each) prior to
transductions. AML cells were cultured in HPGM (Lonza) supplemented with 20 ng/
ml IL-3, G-CSF and Nplate prior to transductions. 293T cells were cultured in
DMEM (Lonza) supplemented with 10% heat-inactivated FCS and 100 U/ml
penicillin/streptomycin.
Lentiviral vectors and transductions. Lentiviral vectors for shRNA
expression: shRNA against CITED2 was obtained from Open Biosystem
(Cambridge, UK, Clone IDs: TRCN0000015654 and TRCN0000015655) and
cloned into a pLKO.1 GFP (kind gift from Prof. Larson, Lund University) and pLKO.1
mCherry vector (obtained by swapping GFP with mCherry). The CITED2 hairpins
were chosen based on previous studies demonstrating that these hairpins had
similar effects when targeting CITED2.1 The P300 PGK-TurboRFP shRNA vector
was obtained from GE Healthcare (Cambridge, UK, #V3SH11243-00EG2033). The
PHLDA3 oligomers were obtained from Invitrogen (Thermo Fisher Scientific,
Landsmeer, the Netherlands) and cloned into the ‘miR-E’ backbone.49 The pLKO.1
mCherry shCBP construct was kindly provided by Walderik Zomerman (UMCG,
University of Groningen). Short hairpin sequences used in this study are listed in
Supplementary table 2. A lentiviral vector expressing BCL2 was constructed by
inserting BCL2 cDNA into the lentiviral expression vector pRRL-IRES-blueberry.
Lentiviral particles were produced as described before.50 After 24 h, medium was
changed to HPGM and after 12 h, supernatant containing lentiviral particles was
harvested and stored at − 80 °C. Cells were transduced with lentiviral particles in
the presence of 4 μg/ml polybrene. For AML and cord blood cells, virus particles
were concentrated using CentriPrep Ultracel YM-50 Filter Units (Merck Millipore,
Billerica, MA, USA) and cells were transduced in two consecutive rounds of 12 h.
FACS analysis. All FACS analyses were performed on an LSRII (Becton
Dickinson, Franklin Lakes, NJ, USA) or BD Accuri (BD Biosciences, Vianen, the
Netherlands) flow cytometer and data were analyzed using FlowJo software. Cells
were sorted on a MoFLo XDP or Astrios (DakoCytomation, Carpinteria, CA, USA).
For Annexin V staining, cells were harvested 4–7 days after lentiviral transduction,
washed in calcium buffer (10 mm HEPES/NaOH, pH 7.4, 140 mm NaCl, 2.5 mm
CaCl2), and stained with 3 μl Annexin V antibody (IQ-products, Groningen, the
Netherlands) in 60 μl calcium buffer for 20 min at 4 °C. Cells were subsequently
Figure 6 Knockdown of CITED2 interferes with AKT-signaling on multiple levels
Reduction of CITED2 levels affects multiple factors involved in regulating AKT-
signaling: (1) Knockdown of CITED2 leads to reduced expression of the transcription
factor SOX4 that stimulates PI3K/AKT signaling. (2) CITED2-low cells show a higher
expression of the Thioredoxin-interacting protein (TXNIP) that reactivates oxidized
PTEN and thereby opposes AKT downstream signaling. (3) Knockdown of CITED2
results in decreased interaction between p53 and its inhibitor MDM2, leading to
increased amounts of p53 protein. (4) Reduction of CITED2 leads to increased
expression of the p53 target gene PHLDA3 that competes with AKT for the binding of
membrane lipids. Decreased AKT signaling results in decreased expression of the
pro-survival gene BCL2 and increased apoptosis
Targeting CITED2 in AML
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washed and resuspended in calcium buffer for analysis. For cell cycle analysis, cell
were resuspended in 200 μl PI-working solution (4 mM trisodium citrate, 20 μg/ml
propidium iodide, 1% v/v Triton X-100, 0,1 mg/ml RNaseA), incubated for 30 min
dark at 4 °C, and analyzed (Ex/Em: 488/610). For some experiments, cells were
treated with following inhibitors as indicated in the figures: C646 (BioVision,
Uithoorn, the Netherlands, 1948), Nutlin-3a (Sigma-Aldrich, St. Louis, MO, USA,
SML0580), MG-149 (kindly provided by FJ Dekker, University of Groningen).
Immunoblotting. Equal amounts of sorted cells were boiled in Laemmli
sample buffer for 10 min and separated by SDS–PAGE (7.5–10% gels) according to
standard protocols. Proteins were transferred onto Immobilon-P PVDF membran
(Millipore) by wet blotting overnight. Membranes were blocked with 5% BSA/PBS
prior to primary antibody incubation. Signal detection was carried out using HRP-
coupled secondary antibodies (DAKO, Amstelveen, the Netherlands) and the
SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific).
Membranes were scanned on a Bio-Rad ChemiDoc MP Imaging System and signal
intensities were quantified using Image Lab software (Bio-Rad, Veenendaal, the
Netherlands). For detection of p-AKT, cells were incubated with 100 ng/ml Igf2 for
12 min prior to resuspension in Laemmli buffer. Primary antibodies for
immunoblotting were: p53 (DO-1, sc-126 Santa Cruz, Huissen, the Netherlands),
acetyl-p53 (Lys382, 2525 S, Cell Signaling, Leiden, the Netherlands), p300 (N15,
sc-584, Santa Cruz), CBP (D6C5, 7389, Cell Signaling), PCAF/KAT2B (ab176316
(EPR2670(N)), abcam/RabMab, Uithoorn, the Netherlands), SIRT1, (B10, sc-74504,
Santa Cruz), HDAC1 (10E2, 5356, Cell Signaling), HDAC2 (3F3, 5113, Cell
Signaling), GFP (B2, SC-9996, Santa Cruz), Pospho-AKT (Ser473, D9E, 4060, Cell
Signaling), β-Actin (C4, SC-47778, Santa Cruz), MDM2 (sc-965, Santa Cruz),
GCN5L2 (C26A10, 3005, Cell Signaling).
RNA isolation and Q-PCR. Total RNA was isolated using the RNeasy Micro
Kit (QIAGEN, Venlo, the Netherlands) following the manufacturer’s instructions. RNA
was reverse transcriped using the iScript cDNA synthesis kit (Bio-Rad). Real-Time
PCR was performed on a CFX Connect System (Bio-Rad) using the SsoAdvanced
SYBR Green Supermix (Bio-Rad). Data were quantified using CFX Manager
software (Bio-Rad) and normalized to values of the housekeeping gene RPS11,
RPL27 or HPRT. Primer sequences are listed in Supplementary information table 1.
Co-immunoprecipitation. Equal numbers of sorted cells were resuspended
in lysis buffer (25 mM Tris-HCL [pH= 7.5], 137 mM NaCl, 1 mM EDTA, 1% NP40,
1 mM DTT, 10% Glycerol) supplemented with 1 × CLAP protease-inhibitor cocktail
(Chymostatin, Leupeptin, Antipain and Pepstatin A, 1 μg/ml each), 0.1 mM PMSF
and 5 mM sodiumbutyrate. IP targeting endogenous protein: Cell lysates were
incubated for 4 h at 4 °C with 2 μg antibody. Immunoprecipitation was carried out
using protein G beads (Dynabeads; Invitrogen, Landsmeer, the Netherlands)
overnight at 4 °C. IP targeting GFP-fusion proteins: Cell lysates were incubated with
25 μl GFP-trap_MA beads (Chromotek, Planegg-Martinsried, Germany) overnight
at 4 °C. Immune complexes were washed three times with lysis buffer, boiled in SDS
lysis buffer and further analyzed by immunoblotting as described above. Primary
antibodies for Co-IP: acetyl-p53 (Lys382; Cell Signaling Technology; catalog number
2525L).
In vivo transplantations into NSG mice. Eight- to 10-week-old female
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were purchased from Charles River
Laboratory (L'Arbresle Cedex, France) and bred in house. Mouse experiments were
performed in accordance with national and institutional guidelines and all
experiments were approved by the Institutional Animal Care and Use Committee
of the University of Groningen (IACUC-RuG). Before transplantations, mice were
sublethally irradiated (2.4 Gy). Following irradiation mice received 3.5 g/l neomycin
in their drinking water for 2 weeks. For the transplantation of human AML cells,
GFP+ CD3− cells were sorted. The mice were injected with 1.5 × 105 sorted GFP+
CD3− cells into the tail vein immediately after sorting. Human cell engraftment was
analyzed in the peripheral blood (PB) by flow cytometry after 6–40 weeks of
transplantation. AML cells were analyzed by exome sequencing and revealed
multiple mutations including NPM1 (VAF 0,35), FLT3-ITD (VAF 0,48) and TET2
(VAF 0,45). VAF: variant allele frequency.
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